Skip to content
DataLookout
Menu

NCT07133633

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 41 versions: 40 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Trial sites expanded: 105 → 108 locations
    • Primary completion moved earlier from Jun 15, 2027 to Mar 29, 2027
  2. Minor Study sites: 106 to 107
  3. Minor Site details revised at 3 of 106 sites
  4. Minor Study sites: 105 to 106
  5. Notable Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 12 of 14 entries
    • Site details revised at 22 of 105 sites
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Site details revised at 1 of 105 sitesv36
  2. Minor Study sites: 104 to 105v35
  3. Minor Site details revised at 3 of 104 sitesv34
  4. Minor Site details revised at 1 of 104 sitesv32
  5. Minor Site details revised at 1 of 104 sitesv31
  6. Minor Study sites: 102 to 104v30
  7. Minor Study sites: 101 to 102v29
  8. Minor Study sites: 100 to 101v28
  9. Minor Site details revised at 1 of 100 sitesv27
  10. Minor Study sites: 99 to 100v26
  11. Minor Study sites: 98 to 99v25
  1. Minor Trial sites expanded: 95 → 98 locationsv24
  2. Minor Trial sites expanded: 89 → 95 locationsv23
  3. Minor Study sites: 88 to 89v22
  4. Minor Study sites: 81 to 88v21
  5. Minor Study sites: 73 to 81v20
  6. Minor Study sites: 69 to 73v19
  7. Minor Study sites: 61 to 69v18
  8. Minor Study sites: 58 to 61v17
  9. Minor Study sites: 57 to 58v16
  10. Minor Study sites: 54 to 57v15
  11. Minor Study sites: 53 to 54v14
  12. Minor Study sites: 52 to 53v13
  13. Minor Study sites: 45 to 52v12
  14. Minor Study sites: 37 to 45v11
  15. Minor Study sites: 34 to 37v10
  16. Minor Study sites: 30 to 34v9
  17. Minor Study sites: 28 to 30v8
  18. Minor Study sites: 19 to 28v7
  19. Minor Study sites: 15 to 19v6
  20. Minor Study sites: 14 to 15v5
  21. Minor Study sites: 3 to 14v4
  22. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Sep 18, 2025 to Sep 26, 2025
    v3
  23. Minor Study description expanded, about 27 wordsv2
  24. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants Achieving Assessment of Spondyloarthritis International Society (ASAS) 40 Response at Week 16
Timeframe: Week 16

Secondary (14)

Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) <2.1 at Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for Spine at Week 16
Change From Baseline in the SPARCC MRI Score for Sacroiliac Joint (SIJ) at Week 16
Change From Baseline in Total Spinal Pain Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 at Week 16
Show 9 moreShow less
Change From Baseline in Nocturnal Spinal Pain at Week 16
Change From Baseline in Assessment of Spondyloarthritis International Society Health Index (ASAS HI) at Week 16
Change From Baseline in Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) at Week 16
Change From Baseline in BASDAI at Week 16
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 16 in the Subgroup of Participants With Enthesitis (MASES>0) at Baseline
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index Linear (BASMI lin) at Week 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) at Week 16
Number of Participants With One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Intervention Due to an AE

Arms and interventions

High-dose tulisokibartExperimental

Participants receive a high dose of tulisokibart.

Medium-dose tulisokibartExperimental

Participants receive a medium dose of tulisokibart.

Low-dose tulisokibartExperimental

Participants receive a low dose of tulisokibart and are rerandomized at week 16 to a medium or high dose of tulisokibart.

PlaceboPlacebo comparator

Participants receive a matched placebo dose and are rerandomized at week 16 to a medium or high dose of tulisokibart.

Drugs: Tulisokibart, Placebo

Sites

108 sites in 14 countries

United States 38, China 9, Ukraine 9, Germany 7, Taiwan 7, Poland 6, Turkey (Türkiye) 6, Brazil 5, Chile 5, United Kingdom 4, Canada 3, Colombia 3, Netherlands 3, South Korea 3